HC Wainwright Comments on Anixa Biosciences, Inc.’s FY2024 Earnings (NASDAQ:ANIX)

Anixa Biosciences, Inc. (NASDAQ:ANIXFree Report) – Equities research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Anixa Biosciences in a report issued on Monday, June 10th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.43) per share for the year, up from their previous estimate of ($0.44). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.44) per share.

Anixa Biosciences Stock Up 3.0 %

Shares of ANIX stock opened at $2.72 on Wednesday. Anixa Biosciences has a 12 month low of $2.21 and a 12 month high of $5.13. The firm has a market cap of $87.06 million, a PE ratio of -7.35 and a beta of 0.84. The stock has a 50 day moving average of $2.87 and a 200-day moving average of $3.53.

Anixa Biosciences (NASDAQ:ANIXGet Free Report) last posted its earnings results on Tuesday, June 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01.

Institutional Trading of Anixa Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Staley Capital Advisers Inc. bought a new stake in Anixa Biosciences in the first quarter valued at $31,000. Simplicity Wealth LLC bought a new stake in Anixa Biosciences in the first quarter valued at $44,000. Virtu Financial LLC grew its position in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after acquiring an additional 5,183 shares during the period. Finally, International Assets Investment Management LLC grew its position in Anixa Biosciences by 274.6% in the fourth quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock valued at $2,110,000 after acquiring an additional 39,820 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 15,009 shares of the business’s stock in a transaction dated Tuesday, April 9th. The stock was bought at an average cost of $3.28 per share, for a total transaction of $49,229.52. Following the completion of the acquisition, the director now directly owns 838,037 shares in the company, valued at $2,748,761.36. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Lewis H. Titterton, Jr. acquired 15,009 shares of the stock in a transaction dated Tuesday, April 9th. The shares were acquired at an average cost of $3.28 per share, for a total transaction of $49,229.52. Following the completion of the transaction, the director now owns 838,037 shares in the company, valued at approximately $2,748,761.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lewis H. Titterton, Jr. acquired 10,738 shares of the stock in a transaction dated Friday, June 7th. The shares were purchased at an average price of $2.52 per share, for a total transaction of $27,059.76. Following the completion of the transaction, the director now owns 848,775 shares of the company’s stock, valued at approximately $2,138,913. The disclosure for this purchase can be found here. Insiders acquired a total of 57,327 shares of company stock worth $152,397 over the last three months. 22.60% of the stock is currently owned by insiders.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

See Also

Earnings History and Estimates for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.